Director, HEOR - Rare Tumor

 

Work Your Magic with us! Start your next chapter and join EMD Electronics.

 

Ready to explore, break barriers, and discover more? We know you’ve got big plans – so do we! Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Healthcare, Life Science, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and planet. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us.  

 

Everything we do in EMD Electronics is to help us deliver on our purpose of being the company behind the companies, advancing digital living. We are dedicated to being the trusted supplier of high-tech materials, services and specialty chemicals for the electronics, automotive and cosmetics industries. We foster a global collaborative organization made up of individuals who have the passion to win, obsess about the customer, are relentlessly curious and act with urgency. Together, we push the boundaries of science to make more possible for our customers.

 

Your Role

 

As a Health Economics & Outcomes Research (HEOR) specialist focusing in rare tumor, you'll generate rigorous medical evidence to support clinical strategy and inform access decisions by population health decision-makers:

• Developing comprehensive value evidence strategies — design and execute systematic literature reviews, real-world evidence (RWE) studies, and patient-reported outcomes (PRO) research to build a robust clinical evidence base
• Leading real-world evidence research programs — design observational study protocols, develop Statistical Analysis Plans (SAPs), oversee execution, and produce final reports that meet the highest methodological standards
• Characterizing disease burden and real-world outcomes — lead epidemiological and database analyses to understand patient populations, treatment patterns, and real-world clinical outcomes that inform access decisions
• Building and validating economic models — develop cost-effectiveness and budget impact models grounded in real-world clinical data to quantify value for population health decision-makers
• Creating evidence-focused materials for population health stakeholders — lead development of AMCP Dossiers, health economics briefs, and supporting documentation that translate HEOR findings into formats addressing the evidence and economic evaluation needs of population health decision-makers and formulary committees
• Supporting field medical communications — partner with field medical to translate complex HEOR findings into clear, scientifically sound materials for health system audiences
• Representing HEOR across cross-functional workstreams — collaborate with medical and market access teams to align on evidence strategy, timelines, and deliverables; serve as the HEOR voice in integrated product workstreams
• Synthesizing insights — integrate insights from access stakeholders, clinical experts, and published literature to continuously strengthen and refine the clinical evidence narrative
• Publishing scientific findings — drive peer-reviewed manuscript publication and conference abstracts to establish clinical credibility and contribute to the scientific literature
• Managing the research portfolio — oversee multiple concurrent HEOR projects, external research partnerships, and budgets to deliver high-quality evidence on time and within scope

 

Who You Are

 

Minimum Qualifications

• Education: Advanced degree (MS or PhD) in Health Economics, Epidemiology, Public Health, Pharmacy, or a closely related field
• Experience: 7+ years of HEOR experience in pharmaceutical, biotechnology, population health, or consulting
• Technical expertise: Demonstrated hands-on experience in real-world evidence study design and execution; proven ability to develop and validate decision-analytic economic models (cost-effectiveness and budget impact)
• Health system knowledge: Strong understanding of how population health organizations, integrated delivery systems, and formulary decision-makers evaluate evid